Botanix Pharmaceuticals (ASX:BOT) is on track to launch its patient experience program for underarm sweating prescription, Sofdra, in the fourth quarter of the 2024 calendar year, according to a Monday filing with the Australian bourse.
The program intends to introduce Sofdra to its first commercial users for initial feedback before being rolled out to larger volumes of patients in the first quarter of 2025.
The clinical dermatology company added that it is on pace to generate first prescriptions from the sales in the coming months, followed by first refills.
Botanix's shares were up 6% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。